Best  	Best  	 JJS	O
practice  	practice  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
pharmacological  	pharmacological  	 JJ	B-NP
management  	management  	 NN	I-NP
of  	of  	 IN	I-NP
hyperthyroid  	hyperthyroid  	 JJ	I-NP
cats  	cats  	 NNS	I-NP
with  	with  	 IN	O
antithyroid  	antithyroid  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
Pharmacological  	Pharmacological  	 JJ	I-NP
management  	management  	 NN	I-NP
of  	of  	 IN	O
feline  	feline  	 JJ	B-NP
hyperthyroidism  	hyperthyroidism  	 NN	I-NP
offers  	offers  	 VBZ	O
a  	a  	 DT	O
practical  	practical  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
option  	option  	 NN	I-NP
for  	for  	 IN	O
many  	many  	 JJ	O
hyperthyroid  	hyperthyroid  	 JJ	B-NP
cats 	cats 	 NNS	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
drugs  	drugs  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
licensed  	licensed  	 VBN	O
for  	for  	 IN	O
cats  	cats  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
decade 	decade 	 NN	O
:  	:  	 :	O
methimazole  	methimazole  	 NNS	B-NP
and  	and  	 CC	O
its  	its  	 PRP$	O
pro-drug  	pro-drug  	 JJ	B-NP
carbimazole 	carbimazole 	 NN	I-NP
.  	.  	 .	O
On  	On  	 IN	O
the  	the  	 DT	O
basis  	basis  	 NN	O
of  	of  	 IN	O
current  	current  	 JJ	O
evidence  	evidence  	 NN	O
and  	and  	 CC	O
available  	available  	 JJ	O
tablet  	tablet  	 JJ	O
sizes 	sizes 	 NNS	O
,  	,  	 ,	O
starting  	starting  	 VBG	B-NP
doses  	doses  	 NNS	I-NP
of  	of  	 IN	O
2·5  	2·5  	 CD	O
mg  	mg  	 NNS	B-NP
methimazole  	methimazole  	 VBP	O
twice  	twice  	 RB	O
a  	a  	 DT	O
day  	day  	 NN	O
and  	and  	 CC	O
10  	10  	 CD	O
to  	to  	 TO	O
15  	15  	 CD	O
mg  	mg  	 NN	B-NP
once  	once  	 IN	O
a  	a  	 DT	O
day  	day  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
sustained  	sustained  	 JJ	O
release  	release  	 NN	B-NP
formulation  	formulation  	 NN	I-NP
of  	of  	 IN	I-NP
carbimazole  	carbimazole  	 NNS	I-NP
are  	are  	 VBP	O
recommended 	recommended 	 VBN	O
.  	.  	 .	O
These  	These  	 DT	O
doses  	doses  	 NNS	O
should  	should  	 MD	O
then  	then  	 RB	O
be  	be  	 VB	O
titrated  	titrated  	 VBN	O
to  	to  	 TO	O
effect  	effect  	 NN	O
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
obtain  	obtain  	 VB	O
circulating  	circulating  	 VBG	O
total  	total  	 JJ	B-NP
thyroxine  	thyroxine  	 NNS	I-NP
( 	( 	 -LRB-	O
TT4 	TT4 	 NNP	B-NP
)  	)  	 -RRB-	O
concentrations  	concentrations  	 NNS	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
lower  	lower  	 JJR	O
half  	half  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
reference  	reference  	 NN	B-NP
interval 	interval 	 NN	I-NP
.  	.  	 .	O
Treated  	Treated  	 JJ	B-NP
cases  	cases  	 NNS	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
monitored  	monitored  	 VBN	O
for  	for  	 IN	O
side-effects 	side-effects 	 NNP	B-NP
,  	,  	 ,	O
especially  	especially  	 RB	O
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
months  	months  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
Some  	Some  	 DT	O
side-effects  	side-effects  	 NN	B-NP
may  	may  	 MD	O
require  	require  	 VB	O
discontinuation  	discontinuation  	 VBN	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
At  	At  	 IN	O
each  	each  	 DT	O
monitoring  	monitoring  	 NN	B-NP
visit 	visit 	 NN	I-NP
,  	,  	 ,	O
clinical  	clinical  	 JJ	B-NP
condition  	condition  	 NN	I-NP
and  	and  	 CC	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
should  	should  	 MD	O
also  	also  	 RB	O
be  	be  	 VB	O
evaluated 	evaluated 	 VBN	O
,  	,  	 ,	O
with  	with  	 IN	O
special  	special  	 JJ	O
attention  	attention  	 NN	O
to  	to  	 TO	O
possible  	possible  	 JJ	O
development  	development  	 NN	O
of  	of  	 IN	O
azotaemia 	azotaemia 	 NN	B-NP
,  	,  	 ,	O
hypertension  	hypertension  	 NN	O
and  	and  	 CC	O
iatrogenic  	iatrogenic  	 JJ	B-NP
hypothyroidism 	hypothyroidism 	 NN	I-NP
.  	.  	 .	O
When  	When  	 WRB	O
euthyroidism  	euthyroidism  	 NN	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
achieved 	achieved 	 VBN	O
,  	,  	 ,	O
monitoring  	monitoring  	 VBG	B-NP
visits  	visits  	 NNS	I-NP
are  	are  	 VBP	O
recommended  	recommended  	 VBN	O
after  	after  	 IN	O
1  	1  	 CD	O
month 	month 	 NN	O
,  	,  	 ,	O
3  	3  	 CD	O
months  	months  	 NNS	O
and  	and  	 CC	O
biannually  	biannually  	 JJ	O
thereafter 	thereafter 	 NN	O
.  	.  	 .	O
Cats  	Cats  	 NNS	O
with  	with  	 IN	O
pre-existing  	pre-existing  	 JJ	O
azotaemia  	azotaemia  	 NNS	B-NP
have  	have  	 VBP	O
shorter  	shorter  	 JJR	O
survival  	survival  	 NN	B-NP
times 	times 	 NNS	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
development  	development  	 NN	O
of  	of  	 IN	O
mild  	mild  	 JJ	O
azotaemia  	azotaemia  	 NN	B-NP
during  	during  	 IN	O
the  	the  	 DT	O
initial  	initial  	 JJ	O
course  	course  	 NN	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
unless  	unless  	 IN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
hypothyroidism 	hypothyroidism 	 NN	B-NP
,  	,  	 ,	O
does  	does  	 VBZ	O
not  	not  	 RB	O
appear  	appear  	 VB	O
to  	to  	 TO	O
decrease  	decrease  	 VB	O
survival  	survival  	 NN	B-NP
time 	time 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
long-term  	long-term  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
medical  	medical  	 JJ	I-NP
management  	management  	 NN	I-NP
require  	require  	 VBP	O
further  	further  	 JJ	O
study 	study 	 NN	O
.  	.  	 .	O
